{"nctId":"NCT02643420","briefTitle":"SPI-2012 vs Pegfilgrastim in the Management of Neutropenia in Participants With Breast Cancer With Docetaxel and Cyclophosphamide (ADVANCE)","startDateStruct":{"date":"2016-01-19","type":"ACTUAL"},"conditions":["Neutropenia","Breast Cancer"],"count":406,"armGroups":[{"label":"Arm 1: SPI-2012 and Docetaxel + Cyclophosphamide (TC)","type":"EXPERIMENTAL","interventionNames":["Drug: SPI-2012","Drug: Docetaxel","Drug: Cyclophosphamide"]},{"label":"Arm 2: Pegfilgrastim and Docetaxel + Cyclophosphamide (TC)","type":"EXPERIMENTAL","interventionNames":["Drug: Pegfilgrastim","Drug: Docetaxel","Drug: Cyclophosphamide"]}],"interventions":[{"name":"SPI-2012","otherNames":["Rolontis®","Eflapegrastim","(HM10460A)"]},{"name":"Pegfilgrastim","otherNames":["Neulasta®"]},{"name":"Docetaxel","otherNames":["Taxotere"]},{"name":"Cyclophosphamide","otherNames":["Cytoxan"]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* New diagnosis of histologically confirmed early-stage breast cancer (ESBC), defined as operable Stage I to Stage IIIA breast cancer\n* Candidate for adjuvant or neoadjuvant TC chemotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance score ≤ 2\n* Absolute neutrophil count (ANC) ≥ 1.5×10\\^9/L\n* Platelet count ≥ 100×10\\^9/L\n* Hemoglobin \\> 9 g/dL\n* Creatinine clearance \\> 50 mL/min\n* Total bilirubin ≤ 1.5 mg/dL\n* Aspartate Aminotransferase per Serum Glutamic-Oxaloacetic Transaminase (AST/SGOT) and Alanine Aminotransferase per Serum Glutamic-Pyruvic Transaminase (ALT/SGPT) ≤ 2.5× Upper Limit of Normal (ULN).\n* Alkaline phosphatase ≤ 2.0×ULN\n\nKey Exclusion Criteria:\n\n* Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix) or life-threatening disease\n* Locally recurrent or metastatic breast cancer\n* Known sensitivity to E. coli -derived products or to any products to be administered during dosing\n* Concurrent adjuvant cancer therapy\n* Previous exposure to filgrastim, pegfilgrastim, or other G-CSF products in clinical development within 12 months prior to the administration of study drug\n* Active infection, receiving anti-infectives, or any serious underlying medical condition that would impair ability to receive protocol treatment\n* Prior bone marrow or stem cell transplant\n* Use of any investigational drugs, biologics, or devices within 30 days prior to study treatment or plans to use any of these during the course of the study\n* Radiation therapy within 30 days prior to enrollment\n* Major surgery within 30 days prior to enrollment","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Duration of Severe Neutropenia (DSN) in Cycle 1","description":"DSN was defined as the number of days of severe neutropenia (absolute neutrophil count \\[ANC\\] \\<0.5×10\\^9/L), after the administration of study drug in Cycle 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.20","spread":"0.503"},{"groupId":"OG001","value":"0.35","spread":"0.683"}]}]}]},{"type":"SECONDARY","title":"Time to Absolute Neutrophil Count (ANC) Recovery in Cycle 1","description":"Time to ANC Recovery was defined as the time from chemotherapy administration until ANC increased to ≥1.5×10\\^9/L after the expected nadir within Cycle 1. Time to ANC recovery was assigned as 0 for participants whose ANC value never dropped below 1.5 x10\\^9/L.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.24","spread":"3.565"},{"groupId":"OG001","value":"3.49","spread":"3.589"}]}]}]},{"type":"SECONDARY","title":"Depth of Absolute Neutrophil Count (ANC) Nadir in Cycle 1","description":"Depth of ANC Nadir was defined as the lowest ANC value after administration of study drug (SPI-2012 or Pegfilgrastim) in Cycle 1.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.56","spread":"3.086"},{"groupId":"OG001","value":"2.53","spread":"3.317"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Febrile Neutropenia (FN) in Cycle 1","description":"FN was defined as an oral temperature \\> 38.3 degrees Celsius (C) (101.0 degrees Fahrenheit \\[F\\]) or two consecutive readings of \\>=38.0 degrees C (100.4 degrees F) for 2 hours and ANC \\<1.0×10\\^9/L.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Severe Neutropenia in Cycle 2, 3 and 4","description":"DSN was defined as the number of days of severe neutropenia (ANC \\<0.5×10\\^9 /L) from the first occurrence of an ANC below the threshold in Cycles 2, 3, and 4.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.13","spread":"0.383"},{"groupId":"OG001","value":"0.09","spread":"0.374"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.326"},{"groupId":"OG001","value":"0.08","spread":"0.273"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.11","spread":"0.362"},{"groupId":"OG001","value":"0.09","spread":"0.281"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Neutropenic Complications in Cycle 1","description":"Neutropenic complications refer to hospitalizations due to neutropenic events and/or the use of anti-infectives due to neutropenia.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Febrile Neutropenia in Cycles 2, 3, and 4","description":"FN was defined as an oral temperature \\> 38.3 degrees C (101.0 degrees Fahrenheit \\[F\\]) or two consecutive readings of \\>=38.0 degrees C (100.4 degrees F) for 2 hours and ANC \\<1.0×10\\^9/L.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Relative Dose Intensity (RDI) of TC (Docetaxel + Cyclophosphamide) in Cycles 1 to 4","description":"RDI was defined as the percentage of the planned dose that each participant actually received during the study, expressed as the total dose received, divided by the total dose planned and multiplied by 100. The planned dose was defined as the dose that would be given if no doses were missed and/or no dose reductions were made for the number of cycles started. The total planned dose was the sum of planned doses over all cycles.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1","spread":"5.47"},{"groupId":"OG001","value":"98.1","spread":"8.45"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":"3.86"},{"groupId":"OG001","value":"99.0","spread":"4.33"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)","description":"An adverse event (AE) is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product or study procedure, whether or not considered related to the medicinal product. A TEAE for Treatment Period is defined as adverse event with an onset date on or after the date of study drug administration through the end of treatment. TEAE for follow up is defined as any new onset or ongoing AE at the end of Treatment. SAE is defined as any AE which meets any of the following criteria: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in a persistent or significant disability/incapacity, results in a congenital anomaly/birth defect, includes important medical events.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"192","spread":null},{"groupId":"OG001","value":"204","spread":null},{"groupId":"OG002","value":"95","spread":null},{"groupId":"OG003","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"36","spread":null},{"groupId":"OG001","value":"29","spread":null},{"groupId":"OG002","value":"8","spread":null},{"groupId":"OG003","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":36,"n":197},"commonTop":["Fatigue","Nausea","Alopecia","Diarrhoea","Lymphocyte count decreased"]}}}